A5065597455- Myasthenia Gravis and Thymoma
- Peripheral Neuropathies and Disorders
- Antifungal resistance and susceptibility
- Nicotinic Acetylcholine Receptors Study
- Monoclonal and Polyclonal Antibodies Research
- Ion channel regulation and function
- Autoimmune Neurological Disorders and Treatments
- Receptor Mechanisms and Signaling
- Systemic Lupus Erythematosus Research
- Neurogenetic and Muscular Disorders Research
- Insect and Pesticide Research
- Multiple Sclerosis Research Studies
- Cardiomyopathy and Myosin Studies
- DNA Repair Mechanisms
- Amyotrophic Lateral Sclerosis Research
- Genomics and Chromatin Dynamics
- Thyroid and Parathyroid Surgery
- Protein Tyrosine Phosphatases
- Parkinson's Disease and Spinal Disorders
- SARS-CoV-2 and COVID-19 Research
- Immunodeficiency and Autoimmune Disorders
- Biotin and Related Studies
- Otitis Media and Relapsing Polychondritis
- Salivary Gland Disorders and Functions
- Tryptophan and brain disorders
Pasteur Hellenic Institute
2014-2024
University of Thessaly
2022
Fondazione IRCCS Istituto Neurologico Carlo Besta
2022
Hadassah Medical Center
2017
Institut Pasteur
2013-2017
Telio (Norway)
2017
KU Leuven
2016
University of Patras
2009-2011
University of Würzburg
1998
Autoimmunity mediated by IgG4 subclass autoantibodies is an expanding field of research. Due to their structural characteristics a key feature antibodies the ability exchange Fab-arms with other, unrelated, molecules, making molecule potentially monovalent for specific antigen. However, whether those disease-associated antigen-specific are mono- or divalent antigens unknown. Myasthenia gravis (MG) muscle kinase (MuSK-MG) well-recognized disease in which predominant pathogenic antibody binds...
Amyotrophic lateral sclerosis (ALS) and myasthenia gravis (MG) are caused, respectively, by motor neuron degeneration neuromuscular junction (NMJ) dysfunction. The membrane protein LRP4 is crucial in the development function of neurons NMJs autoantibodies have been recently detected some MG patients. Because critical role we searched for antibodies ALS patients.We developed a cell-based assay radioimmunoassay with these studied sera from 104 patients.LRP4 were 24/104 (23.4%) patients Greece...
Myasthenia gravis (MG) is an autoimmune disease caused by antibody mediated impairment in the neuromuscular junction. Seronegative MG (SNMG) without antibodies against acetylcholine receptor (AChR) and muscle-specific kinase (MuSK) routine assays accounts for about 20% of all patients.Plasma from 81 Chinese patients previously found to be seronegative was tested AChR MuSK antibodies. These samples were screened (i) a novel, highly sensitive radioimmunoassay antibodies; (ii) cell-based...
Autoantibodies against aquaporin-4 (AQP4), a water channel in CNS astrocytes, are detected ∼50–80% of patients with neuromyelitis optica spectrum disorders (NMOsd), characterized by longitudinally extensive transverse myelitis (LETM) and/or optic neuritis. Although these autoantibodies present an invaluable biomarker for NMOsd and the differential diagnosis multiple sclerosis (MS), anti-AQP4-seronegative remains challenging. We hypothesized that seronegative might have aquaporin-1 (AQP1),...
Several aquaporins (AQPs) are present in the salivary glands, likely contributing to their secretions. AQP dysfunction may contribute gland SS. Antibodies AQP4 and AQP1 detected neuromyelitis optica believed play a pathogenic role. We aimed search for antibodies several AQPs sera from SS patients an effort shed light on mechanisms of SS.We searched six 34 without neurological findings using ELISAs with synthetic peptides corresponding three extracellular domains each AQP, radioimmunoassays...
<h3>Background and Objectives</h3> Autoantibodies against α3-subunit–containing nicotinic acetylcholine receptors (α3-nAChRs), usually measured by radioimmunoprecipitation assay (RIPA), are detected in patients with autoimmune autonomic ganglionopathy (AAG). However, low α3-nAChR antibody levels frequently other neurologic diseases questionable significance. Our objective was to develop a method for the selective detection of potentially pathogenic antibodies, seemingly present only AAG....
Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction (NMJ), mostly associated with acetylcholine receptor (AChR) antibodies. Around 5–10 % MG patients show antibodies to muscle-specific tyrosine kinase (MuSK). Mesenchymal stem cell (MSC) administration has been shown ameliorate muscle weakness in experimental myasthenia (EAMG) model induced by AChR immunization. To investigate efficacy treatment MuSK-related EAMG, clinical and immunological features...
Myasthenia gravis (MG) is usually caused by autoantibodies against muscle nicotinic acetylcholine receptor (AChR), which composed of five subunits (alpha(2)betagammadelta or alpha(2)betaepsilondelta). Current treatments, including plasmapheresis, are nonspecific, causing several side effects. We aim to develop an antigen-specific alternative since the latter removes indispensable plasma components in addition anti-AChR antibodies. developing a method for selective depletion from patients'...